Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
- PMID: 9568710
- DOI: 10.1016/s0092-8674(00)81569-x
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
Abstract
The ligand for osteoprotegerin has been identified, and it is a TNF-related cytokine that replaces the requirement for stromal cells, vitamin D3, and glucocorticoids in the coculture model of in vitro osteoclastogenesis. OPG ligand (OPGL) binds to a unique hematopoeitic progenitor cell that is committed to the osteoclast lineage and stimulates the rapid induction of genes that typify osteoclast development. OPGL directly activates isolated mature osteoclasts in vitro, and short-term administration into normal adult mice results in osteoclast activation associated with systemic hypercalcemia. These data suggest that OPGL is an osteoclast differentiation and activation factor. The effects of OPGL are blocked in vitro and in vivo by OPG, suggesting that OPGL and OPG are key extracellular regulators of osteoclast development.
Similar articles
-
Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.J Cell Biochem. 1999 Feb 1;72(2):251-61. J Cell Biochem. 1999. PMID: 10022507
-
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.J Cell Biol. 1999 May 3;145(3):527-38. doi: 10.1083/jcb.145.3.527. J Cell Biol. 1999. PMID: 10225954 Free PMC article.
-
Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.Am J Pathol. 2000 Mar;156(3):761-7. doi: 10.1016/s0002-9440(10)64942-5. Am J Pathol. 2000. PMID: 10702390 Free PMC article.
-
A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. doi: 10.1006/bbrc.1999.0252. Biochem Biophys Res Commun. 1999. PMID: 10080918 Review.
-
Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.Curr Pharm Des. 2001 May;7(8):613-35. doi: 10.2174/1381612013397807. Curr Pharm Des. 2001. PMID: 11375772 Review.
Cited by
-
Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonates.Arthritis Res Ther. 2012 Oct 18;14(5):R224. doi: 10.1186/ar4063. Arthritis Res Ther. 2012. PMID: 23079134 Free PMC article.
-
Autophagy-linked FYVE containing protein WDFY3 interacts with TRAF6 and modulates RANKL-induced osteoclastogenesis.J Autoimmun. 2016 Sep;73:73-84. doi: 10.1016/j.jaut.2016.06.004. Epub 2016 Jun 18. J Autoimmun. 2016. PMID: 27330028 Free PMC article.
-
Dihydroartemisinin attenuates lipopolysaccharide-induced osteoclastogenesis and bone loss via the mitochondria-dependent apoptosis pathway.Cell Death Dis. 2016 Mar 31;7(3):e2162. doi: 10.1038/cddis.2016.69. Cell Death Dis. 2016. PMID: 27031959 Free PMC article.
-
Osteocyte RANKL: new insights into the control of bone remodeling.J Bone Miner Res. 2012 Mar;27(3):499-505. doi: 10.1002/jbmr.1547. J Bone Miner Res. 2012. PMID: 22354849 Free PMC article. Review.
-
RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival.Cell Death Dis. 2016 Jul 21;7(7):e2300. doi: 10.1038/cddis.2016.213. Cell Death Dis. 2016. PMID: 27441652 Free PMC article.
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
